Literature DB >> 2379548

In vitro myelotoxicity of 2',3'-dideoxynucleosides on human hematopoietic progenitor cells.

D L Du1, D A Volpe, C K Grieshaber, M J Murphy.   

Abstract

Three nucleoside analogues, 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyinosine (ddI), and 2',3'-dideoxycytosine (ddC), were evaluated for their potential myelotoxic effects to normal human hematopoietic progenitor cells. The myeloid (granulocyte-monocyte colony-forming units, CFU-gm) and erythroid (erythroid burst-forming units, BFU-e: and erythroid colony-forming units, CFU-e) committed progenitor cells were exposed to the agents for a 1-h period prior to culture in a microcapillary assay or continuously exposed during the entire culture period. Both ddA and ddI (100 microM) were mildly toxic (less than 50% colony inhibition) to human CFU-gm, BFU-e, and CFU-e following either 1-h or continuous exposures. Marrow progenitor sensitivities to ddA and ddI were indistinguishable. Colony inhibition ranged from 47% to 67% for 1-h ddC exposure (100 microM), values that were comparable to ddA and ddI. Continuous exposure to ddC was highly myelotoxic to human hematopoietic progenitors, with concentrations of 10 and 100 microM suppressing colony formation by 79%-92% and 93%-97%, respectively. These results demonstrate that 1-h and continuous exposures to ddA and ddI were similarly myelotoxic to human hematopoietic cells, whereas a 1-h exposure to ddC was equivalent to ddA and ddI, yet continuous ddC exposure was extremely toxic to marrow cell progenitors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379548

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening.

Authors:  M J Murphy; F Fushimi; R E Parchment; E Barberá-Guillem
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.

Authors:  R E Dornsife; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 3.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 4.  Didanosine, a new antiretroviral drug. A review.

Authors:  R M Franssen; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

5.  A phase II study of temozolomide in advanced untreated pancreatic cancer.

Authors:  M J Moore; R Feld; D Hedley; A Oza; L L Siu
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

6.  Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells.

Authors:  D A Volpe; D L Du; M G Zurlo; N Mongelli; M J Murphy
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

7.  Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis.

Authors:  A Faraj; D A Fowler; E G Bridges; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 8.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.